Immune Thombocytopenic Purpura (ITP) - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 55

Immune Thombocytopenic Purpura (ITP) - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Immune Thombocytopenic Purpura    Pipeline Review, Q4 2010”, provides an overview of the Immune Thombocytopenic Purpura    therapeutic pipeline. This report provides information on the therapeutic development for Immune Thombocytopenic Purpura   , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Immune Thombocytopenic Purpura   . “Immune Thombocytopenic Purpura   -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Immune Thombocytopenic Purpura   .
- A review of the Immune Thombocytopenic Purpura    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Immune Thombocytopenic Purpura    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Immune Thombocytopenic Purpura   .
- A review of the Immune Thombocytopenic Purpura    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Immune Thombocytopenic Purpura    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Immune Thombocytopenic Purpura (ITP) Overview
Therapeutics Development
An Overview of Pipeline Products for Immune Thombocytopenic Purpura (ITP)
Immune Thombocytopenic Purpura (ITP) Therapeutics under Development by Companies
Immune Thombocytopenic Purpura (ITP) Therapeutics under Investigation by Universities/Institutes
Companies Involved in Immune Thombocytopenic Purpura (ITP) Therapeutics Development
Genzyme Corporation
AstraZeneca PLC
GlaxoSmithKline plc
Symphogen A/S
IMMUNOMEDICS, INC
PhytoHealth Corporation
Eisai Inc.
Bio Products Laboratory
SuppreMol GmbH
Universities/Institutes Involved in Immune Thombocytopenic Purpura (ITP) Therapeutics Development
Immune Thombocytopenic Purpura (ITP) Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Gammaplex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IGIV3I Grifols 10% - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Bu Zhong Yi Qi Tang + Zhi Xue Tang + Chuan xin lian kang yan pian mod + Tian Wang Bu xin Dan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bu Zhong Yi Qi Wan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chuan Xin Lian Kang Yan Pian Mod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + MabThera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone USP Micronized - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IVIG + Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Cyclophosphamide + Vincristine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tian Wang Bu xin Dan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zhi Xue Tang - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Immune Thombocytopenic Purpura (ITP) - Featured News
Dec 05, 2010: Amgen's Nplate Maintains Platelet Counts For More Than Five Years In Adults With Chronic Idiopathic Thrombocytopenic Purpura
Nov 10, 2010: Amgen Announces Publication Of Chronic ITP Study With Nplate In New England Journal Of Medicine
Nov 02, 2010: Ligand Announces Approval Of Revolade In Japan
Oct 06, 2010: Symphogen And Swedish Orphan Biovitrum Receive US Orphan Drug Designation For Rozrolimupab In Immune Thrombocytopenia
Sep 24, 2010: Octapharma Publishes Convincing Study Results On Octagam 10% In Hematology
Apr 19, 2010: SuppreMol Receives U.S. Orphan Drug Designation For SM101
Feb 16, 2010: AstraZeneca Signs Agreement With Rigel Pharmaceuticals For Fostamatinib Disodium (R788)
Dec 07, 2009: Amgen Presents Data From First Nplate Study in Children With Chronic ITP
Dec 06, 2009: Nplate Data From MDS Studies Presented at ASH
Sep 07, 2009: SuppreMol Receives Public Research Funding For Its Lead Project SM101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Pandemic Influenza – Pipeline Review, H1 2013
• Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Down Syndrome – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013